Rational Design and Synthesis of Selective PRMT4 Inhibitors: a New Chemotype for Development of Cancer Therapeutics

0 views • Sep 30, 2021
0
Save
Cite
Share

Author(s)

Author Name

Mathew Sutherland

Published 1 Project

Pharmacology And Toxicology

Alice Li

Published 1 Project

Pharmacology And Toxicology

Anissa Kaghad

Published 1 Project

Pharmacology And Toxicology

Dimitrios Panagopoulos

Published 1 Project

Pharmacology And Toxicology

Uploader

Fengling Li

Magdalena Szewczyk

David Smil

Cora Scholten

Published 1 Project

Pharmacology And Toxicology

Lea Bouche

Published 1 Project

Pharmacology And Toxicology

Timo Stellfeld

Published 1 Project

Pharmacology And Toxicology

Cheryl H Arrowsmith

Dalia Barsyte

Masoud Vedadi

Ingo V Hartung

Published 1 Project

Pharmacology And Toxicology

Holger Steuber

Published 1 Project

Pharmacology And Toxicology

Robert Britton

Published 1 Project

Pharmacology And Toxicology

Vijayaratnam Santhakumar

Published 1 Project

Pharmacology And Toxicology

Add New Author

Protein arginine N-methyl transferase 4 (PRMT4) asymmetrically dimethylates arginine residues of histone H3 and non-histone proteins. The overexpression of PRMT4 in several cancers has stimulated interest in the discovery of inhibitors as biological tools and potentially therapeutics. While several PRMT4 inhibitors have been reported, most display poor selectivity against other members of the PRMT family of methyl transferases. Here, we report the structure-based design of a new class of alanine containing 3-arylindoles as potent and selective PRMT4 inhibitors and describe key structure activity relationships for this class of compounds. ### Competing Interest Statement The authors have declared no competing interest.